Year: 2019
Type: review
Abstract: Foxp3‐expressing regulatory T (Treg) cells, which are indispensable for preventing autoimmunity, also suppress effective tumor immunity. Treg cells abundantly infiltrate into tumor tissues, which is often associated with poor prognosis in cancer patients. Removal of Treg cells enhances anti‐tumor immune responses but may also elicit autoimmunity. A key issue in devising Treg‐targeting cancer immunotherapy is, therefore, how to specifically deplete Treg cells infiltrating into tumor tissues without affecting tumor‐reactive effector T cells, while suppressing autoimmunity. This can be achieved by differentially controlling Treg and effector T cells by various ways. In this review, we discuss how tumor‐infiltrating Foxp3 + Treg cells hamper effective anti‐tumor immune responses especially in tumor tissues and how they can be specifically targeted for augmenting tumor immunity but not autoimmunity.
Source: European Journal of Immunology
Authors: Atsushi Tanaka, Shimon Sakaguchi
Language: English
Topic: T-cell and B-cell Immunology
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
Awards: G1582560996, Study of the function and development of regulatory T cells, Molecular basis of Treg-specific TCR signaling regulation, G5731184981, Molecular basis and therapeutic target for autoimmune arthritis, Elucidating the mechanism of autoimmune induction by self-reactive T and regulatory T cells, G8668949081, G8782300437
OpenAlex ID: W2955949220
